KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2025)

Historic Common Equity for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $204.4 million.

  • Adaptive Biotechnologies' Common Equity fell 864.18% to $204.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.4 million, marking a year-over-year decrease of 864.18%. This contributed to the annual value of $202.7 million for FY2024, which is 3427.05% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Common Equity stood at $204.4 million, which was down 864.18% from $179.7 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Common Equity ranged from a high of $725.7 million in Q1 2021 and a low of $179.7 million during Q2 2025
  • In the last 5 years, Adaptive Biotechnologies' Common Equity had a median value of $396.0 million in 2023 and averaged $405.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 3157.46% in 2021, then tumbled by 3899.47% in 2024.
  • Adaptive Biotechnologies' Common Equity (Quarter) stood at $604.1 million in 2021, then fell by 23.16% to $464.2 million in 2022, then crashed by 33.56% to $308.4 million in 2023, then crashed by 34.27% to $202.7 million in 2024, then grew by 0.85% to $204.4 million in 2025.
  • Its Common Equity stands at $204.4 million for Q3 2025, versus $179.7 million for Q2 2025 and $190.4 million for Q1 2025.